Xcout Intel
AAVantgarde Bio competitors & alternatives
The 12 closest competitors and alternatives to AAVantgarde Bio among biotech companies — ranked by similarity to what AAVantgarde Bio actually does, not by market-cap band.
Subscribe to see AAVantgarde Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AAVantgarde Bio
AAVantgarde Bio is an Italian biotechnology company developing adeno-associated virus (AAV) gene therapies for rare genetic diseases, including conditions caused by genes too large to fit into a single AAV vector. Its technology uses dual-AAV approaches to deliver larger therapeutic genes, serving patients with serious inherited disorders and the clinicians who treat them.
AAVantgarde Bio at a glance
AAVantgarde Bio is a biotech company headquartered in Italy. Its most recent funding round, Series B, raised $141M in November 2025. Xcout tracks 3 named people at AAVantgarde Bio, including Megan Zoschg Canniere (Chief Regulatory & Quality Officer). Xcout recorded 1 job posting from AAVantgarde Bio in the last 90 days.
AAVantgarde Bio leadership
- Megan Zoschg CanniereChief Regulatory & Quality Officer
- Alberto AuricchioFounder, AAVANTGARDE / CSO
- Philip LaoSenior Vice President Business Development
AAVantgarde Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $141M | 13 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at AAVantgarde Bio
Xcout recorded 1 job posting from AAVantgarde Bio in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see AAVantgarde Bio's hiring signals →
Top 12 AAVantgarde Bio competitors
Ranked by semantic similarity — how close each company is to AAVantgarde Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
AskBio is a clinical-stage gene therapy company that develops adeno-associated virus (AAV) gene therapies to treat genetic and complex disorders. The company focuses on advancing genetic medicine through its proprietary technology platforms, manufacturing processes, and clinical trials.
Biotechnology
Coave Therapeutics is a clinical-stage biotechnology company headquartered in Paris, France. The company focuses on developing life-changing gene therapies targeting rare ocular and central nervous system diseases.
Biotechnology
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Similar biotech company
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Biotechnology
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Biotechnology
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Similar biotech company
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Biotechnology
Atsena Therapeutics, Inc. is a clinical-stage gene therapy company headquartered in Durham, North Carolina, established in 2019. The firm focuses on developing novel gene therapies to treat debilitating inherited blinding diseases using proprietary vector delivery technologies. Its scientific pipeline aims to address areas of high unmet medical need in ophthalmology.
Similar biotech company
Adverum Biotechnologies is a clinical-stage biotechnology research company headquartered in Redwood City, California. The company focuses on developing novel gene therapies designed to redefine ocular care and treat severe eye diseases.
Biotechnology
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Biotechnology
Hunterian Medicine LLC is a gene-editing company that develops CRISPR-based therapeutics to cure genetic diseases. The company utilizes a patented platform technology with a bidirectional promoter to enable efficient, on-target delivery of CRISPR via a single adeno-associated virus (AAV).
Life Science
ReCode Therapeutics is a clinical-stage genetic medicines company headquartered in Menlo Park, California, and Durham, North Carolina. The company leverages proprietary delivery systems to power a new class of disease-modifying genetic therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AAVantgarde Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AAVantgarde Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →